Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
作者： J M Jürgensmeier , H-J Schmoll , J D Robertson , L Brooks , M Taboada
DOI: 10.1038/BJC.2013.79
关键词: Colorectal cancer 、 Vascular endothelial growth factor 、 Oncology 、 FOLFOX 、 Internal medicine 、 Carcinoembryonic antigen 、 Bevacizumab 、 Hazard ratio 、 Surgery 、 Survival rate 、 Cediranib 、 Medicine
摘要: The prognostic/predictive value of potential vascular endothelial growth factor (VEGF) signalling biomarkers was evaluated retrospectively using samples from two randomized Phase III studies (HORIZON II and III) investigating cediranib in metastatic colorectal cancer (mCRC). Baseline levels VEGF, soluble VEGF receptor-2 (sVEGFR-2) carcinoembryonic antigen (CEA) were measured plasma/serum collected patients participating HORIZON (n=860; FOLFOX/XELOX plus 20 mg (n=502) or placebo (n=358)) (n=1422; mFOLFOX6 (n=709) bevacizumab (n=713)). Median biomarker baseline determined cutoff values for the patient subgroups. data available 88–97% patients/study (>2000 patients). In both studies, high CEA associated with worse outcomes progression-free survival (PFS) overall (OS) independent treatment OS: hazard ratio (HR)=1.35 (95% confidence interval (CI): 1.12–1.63); CEA, HR=1.63 (1.36–1.96); HR=1.32 (1.12–1.54); HR=1.50 (1.29–1.76)). sVEGFR-2 not prognostic PFS/OS. predictive PFS/OS outcome to treatment; low a trend towards improved effect II. treatment-independent PFS OS studies.
nature.com
sci-hub.se 参考文章(35)
A. Andicoechea, F. Vizoso, E. Alexandre, E. Cuesta, M. Cruz Díez, L. Riera, J.L. García-Muñiz, E. Martínez, A. Ruibal, Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer International Journal of Biological Markers. ,vol. 13, pp. 158- 164 ,(1998) , 10.1177/172460089801300307
Sandra F Martins, Rui M Reis, Antonio Mesquita Rodrigues, Fátima Baltazar, Adhemar Longatto Filho, None, Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies World journal of clinical oncology. ,vol. 2, pp. 272- 280 ,(2011) , 10.5306/WJCO.V2.I6.272
Lisa Rydén, Karin Jirström, Monica Haglund, Olle Stål, Mårten Fernö, Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Research and Treatment. ,vol. 120, pp. 491- 498 ,(2010) , 10.1007/S10549-010-0758-6
Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, Christian Manegold, Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) Journal of Clinical Oncology. ,vol. 30, pp. 1114- 1121 ,(2012) , 10.1200/JCO.2011.36.1709
Patrizia Ferroni, Raffaele Palmirotta, Antonella Spila, Francesca Martini, Vincenzo Formica, Ilaria Portarena, Girolamo Del Monte, Oreste Buonomo, Mario Roselli, Fiorella Guadagni, Prognostic Value of Carcinoembryonic Antigen and Vascular Endothelial Growth Factor Tumor Tissue Content in Colorectal Cancer Oncology. ,vol. 71, pp. 176- 184 ,(2006) , 10.1159/000106072
Lawrence E Harrison, Jose G Guillem, Philip Paty, Alfred M Cohen, Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients Journal of The American College of Surgeons. ,vol. 185, pp. 55- 59 ,(1997) , 10.1016/S1072-7515(97)00012-4
DW Miles, SL de Haas, L Dirix, A Chan, X Pivot, P Tomczak, L Provencher, P Delmar, S. Scherer, Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer Cancer Research. ,vol. 70, ,(2010) , 10.1158/0008-5472.SABCS10-P2-16-04
Tatsuro Okamoto, Tomomi Nakamura, Jiro Ikeda, Riichiroh Maruyama, Fumihiro Shoji, Tetsuro Miyake, Hiroshi Wataya, Yukito Ichinose, Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. European Journal of Cancer. ,vol. 41, pp. 1286- 1290 ,(2005) , 10.1016/J.EJCA.2005.03.011
G Des Guetz, B Uzzan, P Nicolas, M Cucherat, J-F Morere, R Benamouzig, J-L Breau, G-Y Perret, Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature British Journal of Cancer. ,vol. 94, pp. 1823- 1832 ,(2006) , 10.1038/SJ.BJC.6603176
Emer O Hanrahan, Anderson J Ryan, Helen Mann, Sarah J Kennedy, Peter Langmuir, Ronald B Natale, Roy S Herbst, Bruce E Johnson, John V Heymach, None, Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clinical Cancer Research. ,vol. 15, pp. 3600- 3609 ,(2009) , 10.1158/1078-0432.CCR-08-2568